Compare Biogen Inc (BIIB) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Meta Platforms Inc — how do they compare? Biogen Inc trades at $195.5 (market cap $28.34B), while Meta Platforms Inc trades at $683.17 (market cap $1.68T). The key difference: Meta Platforms Inc is far larger — about 59.3× Biogen Inc's market cap, and Meta Platforms Inc pays a 0.32% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | META | |
|---|---|---|
Market Cap | $28.34B | $1.68T |
Sector | Health | Media |
52-Week High | $216.63 | $790.00 |
52-Week Low | $122.68 | $525.72 |
Enterprise Value | $30.62B | $1.68T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
META stock trades at $684.48, up 4.23% in the last session, reflecting strong momentum. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $10.44 significantly exceeding the $6.70 estimate. Revenue growth remains impressive, climbing from $116.6B in 2022 to $201.0B in 2025. Technical indicators show a bullish trend, with the stock near key resistance levels, while high RSI readings suggest potential overbought conditions.
The outlook for META is positive, driven by AI innovation like the Muse Spark launch and solid financials, but risks include regulatory lawsuits and high capital expenditure. Analyst consensus is strongly bullish with a $815.44 price target, indicating substantial upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
